Sernova Corp. (T:SVA*CA)

Business Focus: Medical Devices & Implants

Apr 22, 2024 05:00 am ET
Apr 02, 2024 05:00 am ET
Sernova Provides Positive Clinical and Platform Portfolio Update
LONDON, Ontario; BOSTON, Massachusetts - TheNewswuire -  April 2, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, today provided a business update.  Following a review of the company’s therapeutic pipeline and emerging opportunities for its Cell Pouch system platform technologies, Sernova confirms key priorities including its lighthouse program in insulin dependent Type 1 Diabetes plus its intention to advance an IND filing for its post-ope
Mar 11, 2024 06:05 am ET
Sernova Announces Management Developments
LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - March 11, 2024 – Sernova Corp. (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage company focused on providing regenerative medicine therapeutics to patients with chronic conditions, today announced that Nicholas J. Rossettos, CPA has joined Sernova on a consulting basis as interim Chief Financial Officer (CFO).
Jan 29, 2024 05:00 am ET
Sernova Provides Recap of 2023 Accomplishments and Anticipated 2024 Milestones
LONDON, Ontario; Boston, Massachusetts – TheNewswire - January 29, 2024 – Sernova Corp. (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today provided a business update, including a recap of 2023 accomplishments and a preview of certain milestones anticipated in 2024.
Nov 27, 2023 07:19 am ET
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease...
Oct 30, 2023 07:00 am ET
Sernova Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced an update on its conformal coating immune protection technology program, that is used in combination with the Cell...
Oct 27, 2023 07:00 am ET
Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today presented interim positive results from its ongoing Phase 1/2 clinical trial investigating islet allotransplantation into...
Oct 11, 2023 07:00 am ET
Sernova to Provide Two Program Updates in Podium Presentations at 2023 IPITA Congress
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced two oral presentations at the upcoming International Pancreas and Islet Transplant Association (IPITA), International...
Sep 29, 2023 09:50 am ET
Sernova Presents Compelling New Data on the Cell Pouch System™ as a Promising Treatment for Post-Operative Hypothyroidism at the 2023 American Thyroid Association Annual Meeting
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced new preclinical data for its novel cell therapy platform, the Cell Pouch System, as a potential treatment for...
Sep 14, 2023 04:05 pm ET
Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern...
Sep 13, 2023 07:00 am ET
Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will host two investor and analyst conference calls, with corresponding live webcasts. The first of these two...
Sep 07, 2023 07:00 am ET
Sernova Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today provided a development update on its exclusively licensed, proprietary conformal coating immune protection technology, being...
Sep 05, 2023 07:00 am ET
Sernova Corporation Announces the Appointment of Cynthia Pussinen as CEO
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that its Board of Directors has appointed Cynthia Pussinen as Chief Executive Officer and a member of the Board of...
Jul 26, 2023 07:00 am ET
Sernova Expands Leadership Team with Appointment of Modestus Obochi, Ph.D., MBA, as Chief Business Officer
Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the appointment of Modestus Obochi, Ph.D., MBA, a veteran dealmaker and strategic leader with 25+ years of biotech...
Jun 26, 2023 07:50 am ET
Sernova Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions
Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced updated positive interim data from its ongoing Phase 1/2 clinical trial of the Cell Pouch System in patients with...
Jun 22, 2023 05:16 pm ET
Sernova to Present Updated Interim Phase 1/2 Clinical Data on Cell Pouch System™ During Oral Presentation at American Diabetes Association 83rd Scientific Sessions
Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, will be presenting updated interim data from its ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1...
Jun 16, 2023 11:28 am ET
Sernova to Participate in Upcoming Truist Securities Cell Therapy Symposium
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming symposia-cel Truist Securities Cell Therapy Symposium being held June 27, 2023...
May 31, 2023 07:00 am ET
Sernova Announces Executive Alignment and Appoints New Board Chair
Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the outcomes from a strategic and executive leadership review conducted by its Board of Directors (the “Board”)....
May 03, 2023 07:00 am ET
Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of...
Apr 28, 2023 05:00 am ET
Sernova Corp. Announces Voting Results of the 2023 Annual General Meeting of Shareholders
LONDON, Ontario – TheNewswire - April 28, 2023 - Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine company and leader in cell therapeutics focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce results from its Annual General Meeting of Shareholders (the “AGM”), held virtually via live audio webcast on April 27, 2023.
Apr 25, 2023 05:33 pm ET
Concerned Shareholders of Sernova Corp. Wish to Thank All Shareholders
TORONTO, April 25, 2023 /CNW/ - The group of longstanding shareholders (the "Concerned Shareholders") of Sernova Corp (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) (XETRA: PSH) ("Sernova" or the "Company") wishes to thank all shareholders for their participation in electing the next Board of Directors.
Apr 24, 2023 04:05 pm ET
Successful Results Using Sernova’s Cell Pouch System™ with Evotec’s iPSC-Derived Islet-like Clusters for Type 1 Diabetes Presented at the 4th IPITA / HSCI / JDRF Summit
derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostatin (produced by alpha cells and delta cells, respectively), similar to human isletsThe ILCs are cryopreserved during manufacturing,...
Apr 18, 2023 07:00 am ET
Two Independent Proxy Advisory Firms, Including Glass Lewis & Co. LLC., Recommend Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
Sernova Corp. (“Sernova” or the “Corporation”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, is pleased to announce that a second independent, third-party proxy advisory firm, Glass Lewis &...
Apr 18, 2023 06:20 am ET
Two Independent Proxy Advisory Firms, Including Glass Lewis & Co. LLC. Recommend Sernova's Shareholders Vote FOR all Management Nominees on Management's White Proxy
  FollowingInstitutionalShareholderServicespositiverecommendations,GlassLewisisthesecond independent, third-party proxy advisory firm to recommend Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy.  GlassLewisdoesnotbelieveSernova’sdissidentshareholdershavecompiledsufficientlycompellingcase to warrant investor support and refers to their arguments as “incomplete”.  Shareholders who have questions or need assistance with voting their shares should contact Sernova Corp.’sstrategicadvisorandproxysolicitationagentLaurelHillAdvisoryGrou
Apr 18, 2023 06:20 am ET
Two Independent Proxy Advisory Firms, Including Glass Lewis & Co. LLC. Recommend Sernova's Shareholders Vote FOR all Management Nominees on Management's White Proxy
  FollowingInstitutionalShareholderServicespositiverecommendations,GlassLewisisthesecond independent, third-party proxy advisory firm to recommend Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy.  GlassLewisdoesnotbelieveSernova’sdissidentshareholdershavecompiledsufficientlycompellingcase to warrant investor support and refers to their arguments as “incomplete”.  Shareholders who have questions or need assistance with voting their shares should contact Sernova Corp.’sstrategicadvisorandproxysolicitationagentLaurelHillAdvisoryGrou
Apr 17, 2023 08:05 am ET
Concerned Shareholders of Sernova Corp. Stand by their Statements
TORONTO, April 17, 2023 /CNW/ - The group of longstanding shareholders (the "Concerned Shareholders") of Sernova Corp (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) (XETRA: PSH) ("Sernova" or the "Company") maintains that the decrease in share valuation, lack of investor updates and progress relating to clinical studies, deficiencies relating to business development and partnerships, unjustified compensation as well as corporate governance issues have not been addressed by the current board of directors, nor by the current management team. 
Apr 14, 2023 12:53 pm ET
UPDATE -- Institutional Shareholder Services Inc. Recommends Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
Sernova Corp. (“Sernova” or the “Corporation”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, is pleased to announce that Institutional Shareholders Services Inc. (“ISS”) has recommended...
Apr 14, 2023 10:50 am ET
Institutional Shareholder Services Inc. Recommends Senova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy
Sernova Corp. (“Sernova” or the “Corporation”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, is pleased to announce that Institutional Shareholders Services Inc. (“ISS”) has recommended...
Apr 10, 2023 07:00 am ET
Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Toleikis, will present at the upcoming annual Cell & Gene...
Apr 06, 2023 07:00 am ET
Sernova Responds to Dissident Shareholders’ Misleading Statements and Provides Corporate Updates
Sernova Corp. (“Sernova” or the “Company”) (TSX:SVA) (OTCQB: SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today responds to misleading statements made in a press release from a group of dissident shareholders....
Apr 03, 2023 08:00 am ET
Concerned Shareholders of Sernova Corp. Nominate Two Highly Qualified Directors to the Board
Concerned shareholder group has issued an information circular and letter to shareholders outlining reasons for change
Mar 22, 2023 10:58 pm ET
Advance Notice Filed with Sernova Corp. for the Nomination of Two Director Nominees
TORONTO, March 22, 2023 /CNW/ - Betty Anne Millar has filed a notice (the "Notice") with Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) ("Sernova" or the "Company") for the nomination of two highly experienced independent directors to be elected to the board of Sernova at the annual general meeting to be held on April 27, 2023 (the "Meeting"). Mrs. Millar, together with joint actors (the "Group of Shareholders"), holds directly and indirectly an aggregate of 35,789,615 shares, representing approximately 12% of the Company's issued and outstanding common shares of Sernova,
Mar 22, 2023 07:00 am ET
Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell Pouch™ Selected for Oral Podium Presentation at American Diabetes Assoc
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, is pleased to announce that an abstract has been selected for an oral podium presentation at the upcoming American Diabetes Association...
Mar 14, 2023 07:00 am ET
Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an oral presentation at the 4th International Pancreas and Islet Transplant...
Mar 08, 2023 07:00 am ET
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second cohort of its active U.S. Phase 1/2 clinical trial for the treatment of type...
Mar 02, 2023 07:00 am ET
Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheimer...
Jan 30, 2023 07:30 am ET
Sernova Announces Advancements with its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced advancements in its thyroid cell therapy program – one of three cell therapy development programs utilizing the...
Jan 10, 2023 07:00 am ET
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that significant progress has been achieved in its collaboration with Evotec SE (FSE: EVT; NASDAQ: EVO). This progress...
Dec 06, 2022 07:00 am ET
Sernova Corp. Announces CEO Succession Plan and Expanded Management Team
Sernova Corp. (Sernova) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that, as part of a planned leadership succession process, and after a successful 13-year tenure leading the...
Nov 17, 2022 07:30 am ET
Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of its US Phase 1/2 Clinical Trial for Type 1 Diabetes
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second cohort of its active U.S. Phase 1/2 type 1 diabetes (T1D) clinical trial have...
Nov 04, 2022 07:30 am ET
Sernova to Participate in the Stifel Healthcare Conference
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be presenting at the upcoming Stifel Healthcare Conference being held in-person in New York, NY on November...
Nov 03, 2022 07:30 am ET
Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, is pleased to announce, in conjunction with the advancement of its ongoing Phase 1/2 clinical trial of the Sernova Cell Pouch System™...
Oct 24, 2022 06:05 am ET
Sernova Corp. Announces Change of Auditor
London, Ontario – TheNewswire - October 24, 2022 - Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH) announces that it has changed its auditor to KPMG LLP, Chartered Professional Accountants (the “Successor Auditor”) effective October 14, 2022.
Sep 28, 2022 07:30 am ET
Sernova to Participate in the Roth Inaugural Healthcare Opportunities Conference
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative cell therapeutics, today announced it will be presenting at the upcoming Roth Inaugural Healthcare Opportunities Conference being held...
Sep 22, 2022 07:30 am ET
Sernova Announces Full Exercise of Share Purchase Warrants Expiring September 22, 2022
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE / XETRA:PSH), a clinical-stage company and leader in regenerative cell therapeutics, today announced that all remaining share purchase warrants related to the 2020 private placement, expiring on September...
Sep 08, 2022 07:30 am ET
Sernova to Present at H.C. Wainwright Annual Global Investment Conference and LifeSci Partners HealthTech Symposium
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced it will be presenting at the upcoming H.C. Wainwright 24th Annual Global Investment Conference...
Sep 07, 2022 07:30 am ET
Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced the appointment of Daniel Mahony, Ph.D. to its Board of Directors, effective September 30th,...
Sep 01, 2022 07:33 am ET
Sernova Receives Second Tranche Equity Investment from Evotec of $6.8 Million at a Price of $2.50 Per Share
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/ XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that it has completed the second and final tranche of its previously announced private placement...
Aug 30, 2022 07:00 am ET
Sernova to Participate in Live Investor Event Hosted by Leede Jones Gable, Inc.
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that Dr. Philip Toleikis, President & CEO of Sernova Corp, will participate in a fireside chat...
Jun 15, 2022 07:00 am ET
Sernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced that Dr. Philip Toleikis, President & CEO of Sernova Corp, will be participating in the Truist...
Jun 06, 2022 04:30 pm ET
Sernova Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System™ at American Diabetes Association 82nd Scientific Sessions 2022
Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, today announced the presentation of clinical data from its Phase 1/2 clinical trial supporting the potential of...
Jun 02, 2022 11:00 am ET
Sernova Opens the Market
TORONTO, June 2, 2022 /CNW/ - Dr. Philip Toleikis, President and Chief Executive Officer, Sernova Corp. (TSXV: SVA) and his team joined Tanya Rowntree, Global Head of Client Success, Toronto Stock Exchange (TSX), to celebrate the company's graduation from TSX Venture Exchange to Toronto Stock Exchange and open the market.
Jun 01, 2022 04:00 am ET
SERNOVA SHARES to Commence Trading on TSX On June 2, 2022
London, Ontario – TheNewswire - June 1, 2022 – Sernova Corp. (TSXV:SVA); (OTC:SEOVF); (FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, is pleased to announce that its common shares have been approved for listing on the Toronto Stock Exchange (the "TSX") and will commence trading on the TSX at the opening of market on June 2, 2022. Concurrent with the TSX listing, the common shares of the Company will be delisted from the TSX Venture Exchange.
May 17, 2022 07:00 am ET
Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes
Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, and Evotec SE (FSE: EVT; NASDAQ: EVO), a global pharmaceutical and life science company, and leading developer of...
May 09, 2022 11:35 am ET
Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022
LONDON, ONTARIO – TheNewswire - May 9, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that that an abstract has been selected for an oral podium presentation at the upcoming American Diabetes Association (ADA) 82nd Scientific Sessions, to be held from June 3-7, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.
May 05, 2022 07:30 am ET
Sernova to Participate in Multiple U.S. Healthcare Investor Conferences
Sernova Engages Leading U.S.-Based Healthcare Communications Firm to Broaden Awareness of Potential ‘Functional Cure’ Technology for Type 1 Diabetes
Apr 29, 2022 08:05 am ET
Sernova Announces 2022 Annual General Meeting Results
LONDON, ONTARIO – TheNewswire - April 29, 2022 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF)(FSE:PSH), a clinical stage regenerative medicine company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce results from its Annual General Meeting of Shareholders (the “AGM”) held virtually via live audio webcast, on April 28, 2022. Shareholders voted overwhelmingly in favour of all management resolutions proposed in the Company’s Information Circular.
Feb 24, 2022 05:30 am ET
Sernova Corp Ranks Among Top 50 Performing Companies on the 2022 TSX Venture List
Sernova awarded top performer status for two years standing
Jan 20, 2022 05:07 am ET
Sernova Announces Peer Reviewed Publication Demonstrating Safety and Efficacy of a Novel Cell Pouch Cell Therapy Approach for Treatment of Severe Hemophilia A
LONDON, ONTARIO – TheNewswire - January 20, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company developing a potential ‘functional cure’ for chronic diseases is pleased to announce a peer reviewed published scientific journal article highlighting successful development of a novel cell therapy approach for treatment of severe hemophilia A , a serious genetic bleeding disorder caused by missing factor VIII (FVIII) activity in the blood stream.
Jan 10, 2022 08:46 am ET
IIROC Trading Resumption - SVA
VANCOUVER, BC, Jan. 10, 2022 /CNW/ - Trading resumes in:
Jan 10, 2022 08:41 am ET
IIROC Trading Halt - SVA
VANCOUVER, BC, Jan. 10, 2022 /CNW/ - The following issues have been halted by IIROC:
Jan 10, 2022 04:00 am ET
The Principal Investigator in Sernova's Type 1 Diabetes (T1D) Trial Confirms Patients with a History of Hypoglycemia Unawareness Are Now Insulin Independent
LONDON, ONTARIO - TheNewswire - January 10, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to provide a progress update on its Phase 1/2 T1D clinical trial in conjunction with Dr. Piotr Witkowski, the clinical trial’s Principal Investigator at the University of Chicago. Dr. Witkowski was originally scheduled to provide a clinical trial update at the 2022 American Society of Transplant Surgeons (ASTS
Jan 05, 2022 07:00 am ET
Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference
LONDON, ONTARIO – TheNewswire - January 5, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that new interim results from the ongoing safety, tolerability and efficacy Phase I/II clinical trial of Sernova’s Cell Pouch™ will be released on January 10, 2022.
Dec 16, 2021 04:00 am ET
Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium
LONDON, ONTARIO - TheNewswire – December 16, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine and cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce that Dr. Piotr Witkowski, principal investigator of Sernova’s Phase I/II clinical trial will present updated interim results from the ongoing safety, tolerability and efficacy study of Sernova’s Cell Pouch™ in a poster session at the American Society of Transplant Surgeons (ASTS) 22nd A
Dec 14, 2021 04:00 am ET
Sernova Appoints Christopher Barnes as Vice President, Investor Relations & Grants Options/DSUs
LONDON, ONTARIO - TheNewswire - December 14, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage leader in regenerative medicine and cell therapy therapeutics developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce today it has appointed executive Christopher Barnes as Vice President, Investor Relations. Mr. Barnes will lead the execution of Sernova’s investor relations strategy and communications activities.
Dec 02, 2021 04:00 am ET
Sernova Announces Appointment of Executive Chair to Complement its Management Team
LONDON, ON - TheNewswire - December 2, 2021 - Sernova Corp. (TSXV:SVA) (FSE/XETRA:PSH)(OTC:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, is pleased to announce that Frank Holler, member and chairman of the Sernova board of directors, will assume a new role of Executive Chair in order to augment the current leadership team and further support the Company’s evolving corporate and R&D activities and objectives.
Nov 16, 2021 04:00 am ET
Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
LONDON, ON - TheNewswire – November 16, 2021 -- Sernova Corp. (TSXV:SVA)(FSE/XETRA:PSH)(OTC:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18th, 2021 at 10:00am ET.  
Oct 01, 2021 04:00 am ET
Sernova: The Ultimate Combination of Two Proven Technologies as Potential Functional Cure for Type 1 Diabetes and Other Chronic Diseases
Information Session Webinar on Sernova’s Conformal Coating Immune Protection Technology with Dr. Toleikis and International Expert, Dr. Tomei Now Available on Sernova’s Website
Sep 29, 2021 04:00 am ET
Sernova Engages New York-Based LifeSci Advisors as US Investor Relations Partner
Integrated Advisory and Investor Relations Program to Focus on Elevating Company’s Visibility in US Capital Markets Ahead of Projected Corporate Milestones
Sep 16, 2021 04:00 am ET
Sernova Signs Collaboration Agreement to Advance Conformal Coated Immune Protected Therapeutic Cells for Diabetes with the University of Miami
Collaboration to build on positive Cell Pouch T1D Clinical Outcomes and preclinical success in Global Pharmaceutical Collaborations to develop regenerative medicine therapeutic cures without life-long immunosuppression medications across multiple diseases
Aug 09, 2021 04:00 am ET
Sernova to Present Corporate Update at Canaccord Genuity's 41st Annual Growth Conference
London, ON - TheNewswire - August 9, 2021 - Sernova Corp. (TSXV:SVA) (FSE/XETRA:PSH) (OTC:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will provide a corporate update at Canaccord Genuity’s 41st Annual Growth Conference on Wednesday, August 11th, 2021 at 9:30am EDT.  
Jul 05, 2021 04:07 am ET
Sernova Announces 2021 Annual Meeting Results: Shareholders Approve Resolutions with Overwhelming Majority
LONDON, ONTARIO - TheNewswire - July 5, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, held its annual shareholder meeting (the “Meeting”) via the virtual meeting platform of TSX Trust Company for the following purposes:
Jun 30, 2021 04:06 am ET
Industry Veteran Frank Shannon Joins Sernova as VP Clinical Development and Regulatory Affairs
25-Year Industry Veteran in Clinical/Regulatory Therapeutics Development
Jun 28, 2021 04:06 am ET
Jun 07, 2021 04:06 am ET
Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference
Multiple patients with sustained clinical benefit, including positive fasting serum C-peptide (a biomarker of insulin produced by Sernova’s Cell Pouch islets) detected in their bloodstream
Jun 01, 2021 05:06 am ET
Sernova Announces American Transplant Congress 2021 Virtual Connect Abstract Presentation
London, Ontario - TheNewswire - June 1, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes clinical trial will present data and observations from the ongoing study in a presentation at the upcoming American Transplant Congress (ATC) Virtual Connect to be held June 4 - 9, 2021.
May 17, 2021 07:05 am ET
Sernova to Present at Global Partnership Family Office -- HealthCare & Biotechnology TSX Showcase
LONDON, ON – TheNewswire - May 17, 2021 -- Sernova Corp. (TSXV:SVA)(FSE/XETRA:PSH)(OTC:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will present at the virtual Global Partnership Family Office – Healthcare & Biotechnology TSX Showcase on May 19th, 2021. The Showcase is hosted by London, UK based International Deal Gateway (IDG).
May 04, 2021 07:05 am ET
Sernova Announces the Nomination of Seasoned Pharma Executive Dr. Mohammad Azab to its Board of Directors
LONDON, ONTARIO – TheNewswire - May 4, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that seasoned pharmaceutical industry executive, Dr. Mohammad Azab, MB ChB, MSc, MBA, has been nominated by the Company to its Board of Directors.
Apr 28, 2021 07:04 am ET
Sernova KOL Event Highlights Novel Cell Therapy Approach for the Potential Treatment of Thyroid Disease
LONDON, ONTARIO – TheNewswire - April 28, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, announced today the highlights of its first virtual Key Opinion Leader (KOL) event on thyroid disease.
Apr 21, 2021 07:04 am ET
Sernova to Host a Virtual Key Opinion Leader Event on Thyroid Disease and the Potential for its Cell Therapy as a Novel Treatment Approach
LONDON, ONTARIO – TheNewswire - April 21, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announced that it will host a virtual Key Opinion Leader (KOL) event on thyroid disease, current treatment options and the potential of a novel cell therapy treatment approach for postoperative hypothyroidism. The event will take place on Tuesday April 27th, 2021, at 1:00 PM ET.
Apr 14, 2021 07:04 am ET
Sernova Appoints Internationally Renowned Thyroid Disease Expert Dr. Sam Wiseman to its Scientific Advisory Board
Sernova Expands Scientific Advisory Board Expertise for its Innovative Cell Therapy Therapeutic Applications in Endocrine Disorders Including Thyroid Disease
Apr 06, 2021 07:04 am ET
Sernova Announces Presentation at the American Diabetes Association 81st Scientific Sessions
LONDON, ONTARIO - TheNewswire -  April 6, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that lead principal investigator Dr. Piotr Witkowski and the Clinical Trial Investigator Team for its US Phase I/II Type 1 Diabetes clinical trial will present data and observations from the ongoing study in a poster presentation at the upcoming American Diabetes Association’s (ADA) 81st Scientific Sessions to be held June 25 - 29, 2021.
Mar 29, 2021 08:35 am ET
Life Sciences Companies Investors Presentations Now Available for On-Demand Viewing
Life Sciences Investor Forum today announced that the presentations from the March 25th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...
Mar 23, 2021 07:03 am ET
Sernova's Story Front-Page Nationally via Canada's Largest Newspaper Independent
London, ON – TheNewswire - March 23 2021 – TroyMedia Corp. is Canada’s latest Media leader to be drawn to Sernova Corp.’s (TSXV:SVA) (OTC:SEOVF) story and developments.
Mar 22, 2021 10:35 am ET
Sernova to Webcast Live at Life Sciences Investor Forum March 25th
Sernova Corp. (OTCQB:SEOVF)(TSX-V:SVA)(FSE/XETRA:PSH), a leading clinical-stage company focused on developing regenerative medicine therapeutics company, today announced that Dr. Philip Toleikis, President and CEO will present live at...
Mar 19, 2021 08:35 am ET
Virtual Conference for Life Sciences Companies Broadcast Live March 25th, 2021
Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...
Mar 01, 2021 07:03 am ET
Sernova Announces Closing of C$23 Million Bought Deal Financing Including Full Exercise of Over-Allotment Option
LONDON, ONTARIO – TheNewswire - March 1, 2021 – Sernova Corp. (“Sernova” or the “Company”) (TSXV:SVA) (OTC:SEOVF) (Frankfurt/Xetra:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that it has closed its previously announced bought deal financing of 16,700,000 units of the Company (the “Units”) at a price of C$1.20 per Unit (the “Issue Price”), and the exercise in full of the Over-Allotment Option of 2,505,000 Units at the Issue Price, for aggregate gross proceeds to the Company of approximately C$23,046,000 (the “Offering”).
Feb 25, 2021 07:02 am ET
Sernova Corp. Selected for the TSX Venture Stock Exchange's 2021 Venture 50 List of Top Performing Listed Companies
London, Ontario - TheNewswire - February 25, 2021 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (Frankfurt/Xetra:PSH), a clinical-stage company and leader in regenerative medicine therapeutics is pleased to announce that the TSX Venture Stock Exchange (TSX Venture) has recognized Sernova as a 2021 Venture 50 company, showcasing the top 50 performing listed companies.
Feb 24, 2021 05:02 am ET
Sernova Obtains Final Prospectus Receipt for $20 Million Bought Deal
LONDON, ONTARIO - TheNewswire – February 24, 2021 – Sernova Corp. ("Sernova" or the "Company") (TSXV:SVA) (OTC:SEOVF) (Frankfurt/Xetra:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce it has received a receipt for its final short form prospectus dated February 24, 2021 (the "Final Prospectus") in connection with its previously announced bought deal offering of 16,700,000 units of the Company (the "Units") at a price of C$1.20 per Unit for gross proceeds of approximately C$20,040,000 (the "Offering"). Canaccord Genuity Corp. and Leede Jones Gabl
Feb 05, 2021 04:56 pm ET
BTV News Alert Video: Sernova Corp. - A Functional Cure for Type I Diabetes
Vancouver, British Columbia--(Newsfile Corp. - February 5, 2021) - Sernova Corp. (TSXV: SVA) (OTCQB: SEOVF) - The company announces collaborations with global pharmaceutical companies to work with the Sernova Cell Pouch System.
Feb 04, 2021 08:58 am ET
IIROC Trading Resumption - SVA
VANCOUVER, BC, Feb. 4, 2021 /CNW/ - Trading resumes in:
Feb 04, 2021 08:44 am ET
Sernova Upsizes Previously Announced Bought Deal Public Offering to C$20 Million
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Feb 04, 2021 08:36 am ET
IIROC Trading Halt - SVA
VANCOUVER, BC, Feb. 4, 2021 /CNW/ - The following issues have been halted by IIROC:
Feb 04, 2021 07:02 am ET
Sernova Shares Accepted for Trading on the Electronic Trading Platform Xetra in Germany
LONDON, ONTARIO – TheNewswire - February 4, 2021 – Sernova Corp. (TSXV:SVA) (OTCQB:SEOVF) (FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce the start of trading of Sernova shares on Xetra, the electronic trading system of Deutsche Börse AG in Germany (German Securities Identification Number (WKN): A0LBCR, International Securities Identification Number (ISIN): CA81732W1041, German Ticker-Symbol: PSH).
Feb 03, 2021 04:20 pm ET
Sernova Corp. Announces C$10 Million Bought Deal Offering of Units
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Feb 03, 2021 07:02 am ET
Sernova's Collaborator to Present Cell Pouch(TM) Thyroid Transplant Study Results at the American Association of Endocrine Surgeons 2021 Annual Meeting
LONDON, ONTARIO – TheNewswire - February 3, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that Dr. Sam Wiseman, BSc, MD, FRCSC, FACS of the University of British Columbia and co-investigator of Sernova’s Cell Pouch Hypothyroid treatment program will present preclinical data in an oral presentation at the American Association of Endocrine Surgeons (AAES) 2021 Annual Meeting taking place April 25-27, 2021. Dr. Sam Wiseman, Professor, Richard J. Finley Scholar, and Director of Research at the Dep
Feb 02, 2021 07:02 am ET
(RADIO INTERVIEW) Sernova Continues to Draw Media Attention: Global News London Goes In-Depth with Dr. Philip Toleikis
London, ON – TheNewswire – February 2 2021 - On the heels of recent partnership interest and conference presentations,  Global News London’s Jess Brady took time took time to truly explore the pertinence of Sernova’s regenerative cell pouch technology.
Jan 28, 2021 06:01 am ET
Sernova Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders
Sernova’s Cell Pouch platform and cell therapy expertise being used in multiple collaborations with global pharmaceutical companies
Jan 25, 2021 07:01 am ET
Sernova Announces Warrants Exercise for Proceeds of $4.3 Million and Early Conversion of Debenture
LONDON, ONTARIO – TheNewswire - January 25, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company is pleased to announce that in recent weeks it has received gross proceeds of $4.3 million pursuant to the exercise of more than 14 million warrants. Sernova intends to use the proceeds of the warrants exercised to support the Company’s clinical diabetes programs including its US Phase I/II diabetes clinical trial, diabetes stem cell-derived technologies and to also accelerate treatments for hypothyroid disease and hemophilia A.
Jan 21, 2021 07:01 am ET
Sernova CEO to Present Regenerative Medicine Therapeutics Platform Update at the 2021 Cell & Gene Therapy Meeting on the Med
LONDON, ONTARIO – TheNewswire - January 21, 2021 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company announced today that Dr. Philip Toleikis, President and CEO has been invited to participate at the Cell & Gene Virtual Meeting on the Med, and available on-demand to attendees beginning Thursday, April 6 to 9. Dr. Toleikis will deliver a corporate update on Sernova’s regenerative medicine therapeutics platform including our US clinical cell therapy diabetes program as part of the 2021 Company Presentations at the Cell & Gene Meeting on the M
Jan 18, 2021 04:01 am ET
Sernova Principal Investigator Presents Additional Positive Preliminary Safety and Efficacy Data from Ongoing U.S. Phase I/II Cell Pouch Clinical Trial for Type-1 Diabetes
Sernova’s Cell Pouch System shows sustained clinical benefit in study patients with type 1 diabetes through multiple efficacy indicators and ongoing safety and tolerability
Jan 15, 2021 01:45 pm ET
IIROC Trading Resumption - SVA
VANCOUVER, BC, Jan. 15, 2021 /CNW/ - Trading resumes in:
Jan 15, 2021 01:27 pm ET
IIROC Trading Halt - SVA
VANCOUVER, BC, Jan. 15, 2021 /CNW/ - The following issues have been halted by IIROC:
Jan 15, 2021 12:01 pm ET
Sernova Principal Investigator Presents Additional Positive Preliminary Safety and Efficacy Data from Ongoing U.S. Phase I/II Cell Pouch Clinical Trial for Type-1 Diabetes
Sernova’s Cell Pouch System shows sustained clinical benefit in study patients with type 1 diabetes through multiple efficacy indicators and ongoing safety and tolerability
Dec 18, 2020 07:12 am ET
Dec 16, 2020 07:12 am ET
(PODCAST) Sernova's Visibility Increases Ahead of Holidays
London, Ontario - TheNewswire – December 16, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) continues to gain attention this week as the company shares have reached new levels over the past few days. Dr. Philip Toleikis, President and CEO of Sernova was interviewed earlier this week by Pat Beechinor of MarketRadio.com.
Dec 11, 2020 11:12 am ET
Sernova Corp. Responds to Market Activity
LONDON, ONTARIO – TheNewswire - December 11, 2020 – At the request of IIROC (“Investment Industry Regulatory Organization of Canada”), Sernova Corp. (“Sernova” or the “Company”) (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) wishes to confirm that the Company’s management is unaware of any material or undisclosed information or change in the Company’s operations that would account for the recent increase in price and market activity.
Dec 03, 2020 07:12 am ET
Sernova Medical Advances Gain Media Attention
London, Ontario - TheNewswire - December 3, 2020 - Interest in Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) is growing rapidly.
Nov 30, 2020 07:11 am ET
Sernova Announces Clinical Trial Investigator Presentation at the ASTS 21st Winter Symposium
LONDON, ONTARIO - TheNewswire - November 30, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company, is pleased to announce that Dr. Piotr Witkowski, principal investigator in Sernova's ongoing Phase I/II clinical trial, A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation will present data and observations from the trial in an oral presentation delivered at the American Society of Transplant Surgeons 21st Annual State of the Art Winter Symposium.
Nov 18, 2020 07:11 am ET
Sernova Provides Clinical Update on U.S. Phase I/II Cell Pouch(TM) Trial for Type 1 Diabetes
LONDON, ONTARIO – TheNewswire - November 18, 2020 – Sernova Corp (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company developing a ‘functional cure’ for insulin-dependent diabetes, hemophilia A, and other diseases, provides an update on its U.S. Phase I/II (safety/efficacy) clinical trial of its Cell Pouch System for type 1 diabetes (T1D) at the University of Chicago.
Oct 30, 2020 07:10 am ET
Sernova Announces 3-Month Extension of Warrants
London, Ontario - TheNewswire - October 30, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, announces that, subject to acceptance by the TSX Venture Exchange, it intends to extend the expiry date of 11,016,000 outstanding share purchase warrants (the "Warrants") issued pursuant to a private placement that closed in two tranches. The Warrants currently expire on November 14, 2020, and November 21, 2020. Each Warrant is exercisable into an equal number of common shares of the Company at a price of $0.35. If accepted by the TSX, the new expi
Oct 29, 2020 01:10 am ET
(Exclusive) Sernova Presents at TSX Life Sciences Investor Day: Available Now!
LONDON, ONTARIO – TheNewswire - October 29, 2020 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, was invited by the TMX Group to present today at the first-ever TSX Life Sciences Investor Day hosted by the Toronto Stock Exchange and the TSX Venture Exchange. Dr. Philip Toleikis, President and CEO, provided a virtual investor presentation to attendees.
Oct 27, 2020 07:10 am ET
Sernova to Present at TSX Life Sciences Investor Day
Sernova Retains Integral Wealth Securities for Market Making Services
Sep 24, 2020 07:09 am ET
Sernova to Present at Virtual BIO Investor Forum
Sernova to deliver corporate update with focus on value-driving events: technology acquisition, licensing and research collaboration
Sep 23, 2020 07:09 am ET
Sernova Closes Oversubscribed Private Placement and Accelerates Development Programs
LONDON, ONTARIO - TheNewswire – September 23, 2020 – Sernova Corp. ("Sernova" or the "Company") (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) is pleased to announce that it has closed its non-brokered private placement announced on September 9, 2020. The Company received over-subscriptions of $0.7 million, increasing the total amount of the private placement to $3.7 million.
Sep 10, 2020 07:09 am ET
Sep 09, 2020 07:09 am ET
Sernova Announces Up to $3 Million Private Placement Financing with a Lead Order of $2 Million
LONDON, ONTARIO - TheNewswire – September 9, 2020 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, is pleased to announce that the Company has secured a $2 million lead order in connection with a proposed non-brokered private placement.
Aug 04, 2020 05:08 am ET
Sernova Enters into Exclusive Worldwide License Agreement with University of Miami for Therapeutic Cell Immune Protection Technologies
Sernova expands its intellectual property portfolio and capabilities to develop first-in-class cell therapy solutions for type 1 diabetes and other chronic diseases that eliminate the need for life-long immunosuppression drugs
Jul 16, 2020 07:07 am ET
Dr. Anke M. Schulte Joins Sernova Global Advisory Board
Veteran Pharmaceutical Executive in Regenerative Medicine Therapeutics to Contribute Corporate Development/ Strategic Expertise to Sernova
Jun 18, 2020 07:06 am ET
Sernova Highlights Positive Results Presented at the American Diabetes Association's Virtual 80th Scientific Sessions
LONDON, ONTARIO – TheNewswire - June 18, 2020 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company,  highlights positive results from its submitted abstract entitled “Clinical Validation of the Implanted Pre-Vascularized Cell Pouch™ as a Viable, Safe Site for Diabetes Cell Therapy,” selected for presentation at the American Diabetes Association’s (ADA) 80th Scientific Sessions held virtually June 12-16, 2020.
Jun 15, 2020 07:06 am ET
Sernova Completes Acquisition of Cellular Local Immune Protection Technology
LONDON, ONTARIO – TheNewswire - June 15, 2020 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, is pleased to announce it has completed the acquisition of cellular local immune protection technology from Converge Biotech, Inc. (“Converge”).
Jun 08, 2020 06:06 am ET
Sernova to Acquire Cellular Local Immune Protection Technology Accelerating Expansion of its Regenerative Medicine Therapeutics Platform
London, Ontario - TheNewswire - June 8, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today its acquisition of an innovative cellular immune protection technology. This acquisition represents a strategic accelerator for expansion of Sernova’s total regenerative medicine cell therapy therapeutics platform.
Jun 03, 2020 07:06 am ET
Sernova to Present Clinical Validation of the Cell Pouch as a Viable, Safe Site for Diabetes Cell Therapy at the American Diabetes Association's Virtual 80th Scientific Sessions
LONDON, ONTARIO – TheNewswire - June 3, 2020 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company,  is pleased to announce that its submitted abstract entitled “Clinical Validation of the Implanted Pre-Vascularized Cell Pouch as a Viable, Safe Site for Diabetes Cell Therapy” has been selected for presentation at the upcoming American Diabetes Association’s (ADA) Virtual 80th Scientific Sessions to be held June 12-16, 2020. Sernova’s presentation (ePoster 205-LB) will be available to conference attendees beginning June 13, 2020, at 11:00
May 29, 2020 06:05 am ET
AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A
Sernova to utilize AgeX’s UniverCyteTM gene technology to generate transplantable, universal immune-protected therapeutic cells for Sernova’s Cell Pouch™ Platform
May 26, 2020 04:05 am ET
Sernova Announces Change of Location of Annual Meeting of Shareholders
LONDON, ONTARIO - TheNewswire – May 26, 2020 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) (the "Corporation" or "Sernova") announces that the Board of Directors of the Corporation have considered current COVID-19 public health restrictions and determined it to be in the best interests of the Corporation and its shareholders to change the location of the Corporation's annual meeting of shareholders ("AGM") to the offices of Sernova at 700 Collip Circle, Suite 114, London, Ontario N6G 4X8.  The AGM will be held on Friday, May 29, 2020, at 12:00 p.m. (Eastern Time). Shareholders are reminded
May 19, 2020 07:05 am ET
Sernova Highlights Achievements of the HemAcure Hemophilia Cell Therapy Program Presented at ASGCT
Sernova’s Cell Pouch transplanted with Factor VIII corrected human cells shows robust functional blood clotting improvement demonstrating a novel first-in-class ex vivo gene therapy cell-based approach for the treatment of hemophilia A
May 12, 2020 07:05 am ET
Sernova Announces Presentation of HemAcure Hemophilia Program Results at 23rd Annual Meeting of the American Society of Gene and Cell Therapy
London, Ontario - TheNewswire - May 12, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, is pleased to announce that the Horizon 2020 HemAcure Consortium will present scientific results of the consortium’s research in an abstract entitled Combined Gene and Cell Therapy for the Treatment of Hemophilia A within an Implantable Therapeutic Device in an oral presentation during the ASGCT 23rd Annual Meeting, which is being held in virtual format May 12-15, 2020.  The abstract will be presented on May 15 at 11:30 am EDT.
Apr 27, 2020 07:04 am ET
Sernova Advances Annual General Meeting and CEO Teleconference to Friday May 29
LONDON, ONTARIO – TheNewswire - April 27, 2020 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) announced today, with its continued COVID-19 vigilance, social gathering size restrictions in effect imposed by public health authorities and the now anticipated near term relaxation of certain COVID-19 public health-related restrictions, the Annual General Meeting (AGM) and CEO teleconference call originally scheduled for Thursday, April 30, 2020, has been adjourned to May 29, 2020, at 9:00 a.m. and 10:00 a.m. (Pacific Time), respectively. All other aspects of the AGM remain the same as published
Apr 21, 2020 07:04 am ET
Important COVID-19 Safety Measures for Sernova's 2020 Annual Meeting of Shareholders
LONDON, ONTARIO - TheNewswire – April 21, 2020 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today that it is implementing safety measures for its upcoming Annual Meeting of Shareholders (“AGM”) to be held in Vancouver, BC on April 30, 2020, in response to public health authority guidelines issued concerning the COVID-19 pandemic.
Mar 24, 2020 07:03 am ET
Sernova Provides Corporate Update and Outlook for 2020
LONDON, ONTARIO - TheNewswire - March 24, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, today provided a corporate update and outlook for 2020.
Feb 17, 2020 06:02 am ET
Sernova to Present Corporate Update at Noble Capital Markets Investor Conference
LONDON, ONTARIO – TheNewswire - February 17, 2020 – Sernova Corp (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine therapeutics leader announced today that President and CEO Dr. Philip Toleikis will present at NobleCon16 on February 18th at 2:00 p.m. NobleCon16 is Noble Capital Markets' 16th Annual Investor Conference featuring emerging growth companies being held at the Seminole Hard Rock Hotel & Casino, Hollywood, Florida from February 17-18th, 2020.
Feb 13, 2020 07:02 am ET
Sernova Achieves Positive Efficacy Endpoint in Phase I/II Clinical Trial for Type 1 Diabetes
Most advanced subject in the clinical trial continues to show positive indicators of islet function following islet transplant into the Cell Pouch
Oct 24, 2019 07:30 am ET
Sernova Announces Biotech Veteran as New Chief Financial Officer
LONDON and ONTARIO, California, Oct. 24, 2019 /CNW/ -- Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company, is pleased to announce that Mr. David Swetlow, CPA, CA, has joined Sernova as Chief Financial Officer.
Oct 24, 2019 07:30 am ET
Sernova Announces Biotech Veteran as New Chief Financial Officer
LONDON and ONTARIO, California, Oct. 24, 2019 /PRNewswire/ -- Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company, is pleased to announce that Mr. David Swetlow, CPA, CA, has joined Sernova as Chief Financial Officer.
Oct 17, 2019 09:00 am ET
InvestmentPitch Media Video Discusses Sernova Corp's Further Validation of Cell Pouch and Therapeutic Cell Performance in Type-1 Diabetes - Video Available on Investmentpitch.com
Vancouver, British Columbia--(Newsfile Corp. - October 17, 2019) - Sernova Corp. (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, has reported findings that further validate Cell Pouch™ and therapeutic cell performance in Type-1 diabetes. The Cell Pouch™ is a novel implantable device, that is transplanted with therapeutic cells such as insulin producing islets. 
Oct 16, 2019 07:10 am ET
Sep 17, 2019 07:09 am ET
Sernova Renews Frontier Flex for Canadian Investor Relations and Marketing
LONDON, ONTARIO - TheNewswire – September 17, 2019 – Sernova Corp. (TSXV:SVA) (OTCQB:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, announces that it has renewed the engagement of Frontier Flex, an investor relations (IR) and marketing group based in Toronto, Ontario Canada to provide Canadian IR and strategic marketing services.
Sep 10, 2019 07:09 am ET
Sernova Completes Oversubscribed Private Placement of $4,684,564
LONDON, ONTARIO – TheNewswire – September 10, 2019 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) announces it has completed on Monday a non-brokered private placement of $4.685 million, pursuant to which Sernova issued a total of 23,422,822 Units in three closings (August 16, 2019, August 30, 2019 and September 9, 2019).
Sep 03, 2019 07:09 am ET
Sernova Announces Second Closing of Private Placement
LONDON, ONTARIO - TheNewswire - September 3, 2019 – Sernova Corp. (TSXV:SVA) (FSE:PSH) (OTC:SEOVF), a clinical-stage regenerative medicine company, is pleased to announce that it has completed a second closing of $2,251,065 of its non-brokered private placement, (announced on July 25, 2019) of which an additional $67,400 was closed under the “Existing Shareholder Exemption.” Total proceeds to date are $4,584,565.
Aug 19, 2019 07:08 am ET
Jul 25, 2019 06:07 am ET
Sernova Announces Up to $3 Million Private Placement Financing
London, Ontario – TheNewswire - July 25, 2019 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) announces a proposed private placement (the “Offering”) of up to $3 million in units (the “Units”) of the Company at a price of $0.20 per Unit including up to $1 million in Units that are being offered pursuant to the “existing shareholder prospectus exemption.”
Jul 17, 2019 01:07 am ET
Sernova's Phase I/II US Clinical Trial for Type-1 Diabetes Advances Following Positive Preliminary Safety and Efficacy Data
CEO to participate in conference call with Sernova Shareholders on July 18 at 10:00 am (EDT)
Jul 03, 2019 03:07 am ET
Sernova Corp Presents Positive Preliminary Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes
Sernova’s Cell Pouch (TM) with transplanted islet cells reached primary safety measurements and clinically significant efficacy outcomes including glucose-stimulated C-peptide and the release of insulin in the first patient transplanted
Jun 27, 2019 07:06 am ET
Sernova's Principal Investigator to Present Interim Data from the Company's Ongoing Phase I/II Cell Pouch Clinical Trial at the 17th World Congress of the International Pancreas and Islet Transplant A
LONDON, ONTARIO - TheNewswire - June 27, 2019 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF), a clinical-stage regenerative medicine company is pleased to announce that Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, will present, in an oral podium session, early preliminary data and observations from Sernova’s ongoing clinical trial, entitled A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation, at the 17th World Congress of the International Pancreas and Islet Transplantation Association (IPIT
May 21, 2019 07:05 am ET
Sernova Corp Announces Appointment of Deborah Brown to its Board of Directors
LONDON, ONTARIO / TheNewswire / May 21, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) a clinical-stage regenerative medicine company, today announced the appointment of Ms. Deborah Brown to its Board of Directors.
Apr 30, 2019 07:04 am ET
Sernova Announces Collaboration to Advance Therapeutic Cell Pouch Technologies for the Treatment of Hypothyroidism
Co-investigators, Dr. Sam Wiseman of the University of British Columbia and Sernova Corp awarded the prestigious Transplant Research Foundation of British Columbia Venture Grant
Apr 11, 2019 07:04 am ET
Sernova Announces First Transplantation of Therapeutic Cells in Cell Pouch for the Company's Phase I/II U.S. Clinical Study for Diabetes
LONDON, ONTARIO / TheNewswire / April 11, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage regenerative medicine company today announced the first Cell Pouch™ transplant of insulin-producing cells in its U.S. Phase I/II clinical trial evaluating the safety and efficacy of the Cell Pouch for Clinical Islet Transplantation in type 1 diabetes.  
Feb 11, 2019 07:02 am ET
Sernova Corp Announces First Patient Implanted with Sernova's Cell Pouch(TM) in a Phase I/II US Clinical Trial for the Treatment of Hypoglycemia Unawareness in Subjects with Type 1 Diabetes
LONDON, ONTARIO / TheNewswire / February 11, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage regenerative medicine company today announced the first patient implanted with Sernova’s Cell Pouch™ in the Phase I/II clinical trial evaluating the safety and efficacy of Sernova’s Cell Pouch™ for Clinical Islet Transplantation in type 1 diabetes.
Jan 30, 2019 07:01 am ET
Sernova Announces the Appointment of Dr. David Lillicrap, M.D. to its Scientific Advisory Board
Sernova Adds Scientific Advisory Board Expertise as it Broadens its Therapeutic Cell Therapy Applications for Rare Blood Diseases
Jan 28, 2019 04:01 am ET
Sernova to Participate on Diabetes Panel and Present at NobleConXV, 15th Annual Investor Conference January 28th - 29th, 2019
LONDON, ONTARIO / TheNewswire / January 28, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company announced today that Dr. Philip Toleikis, President and CEO will present the latest company overview and is invited to participate on the Diabetes Panel at NobleConXV — Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Fla., on Monday January 28th at 11:00 a.m. Eastern Time.
Jan 17, 2019 07:01 am ET
Sernova Announces Successful Enrollment Approaching 50% of Subjects in its U.S. Phase I of II Cell Pouch Diabetes Clinical Trial
LONDON, ONTARIO / TheNewswire / January 17, 2019 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF), a clinical-stage regenerative medicine company today announced the enrollment of the first three of seven subjects in its Phase I/II trial of Sernova’s Cell Pouch™ for Clinical Islet Transplantation in type 1 diabetes.
Dec 20, 2018 02:12 am ET
Nov 20, 2018 06:11 am ET
Sernova Highlights Achievements from the HemAcure Consortium in Developing a Novel Cell-Based Therapy for Hemophilia A
A series of breakthroughs from the International HemAcure Consortium provides a novel cell-based treatment approach for people living with Hemophilia A which could reduce or eliminate the need for lifelong Factor VIII infusions
Nov 09, 2018 04:11 am ET
Sernova Retains FronTier Flex for Canadian Investor Relations and Marketing
LONDON, ONTARIO – November 9, 2018– Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine company, announces that it has engaged FronTier Flex, an investor relations (IR) and marketing group based in Toronto, Ontario Canada to provide Canadian IR and strategic marketing services.
Nov 06, 2018 04:11 am ET
Sernova Establishes Comprehensive North American Investor Relations and Communications Strategy
US Program to Focus on Raising Company’s Visibility Through Engagement
Oct 23, 2018 04:10 am ET
Sernova-HemAcure Consortium to Present Achievements in Development of a Regenerative Medicine Approach to Treat Hemophilia A
LONDON, ONTARIO –October 23, 2018 – Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) a regenerative medicine company, announces that Dr. Philip Toleikis, Sernova’s President and CEO, along with the additional Horizon 2020 HemAcure Consortium Leaders, will present an overview of key achievements in developing a novel cell-based therapy for the treatment of Hemophilia A, in a publicly accessible webinar.
Jul 23, 2018 06:00 am ET
Sernova Completes Oversubscribed Private Placement of $2,754,000
Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) announces it has completed a non-brokered private placement of $2.754 million, pursuant to which Sernova issued a total of 11,016,000 special warrants in two closing (July 13, 2018, and July 20,...
Jul 16, 2018 06:00 am ET
Sernova Announces $2,000,000 First Closing of Private Placement
Sernova Corp. (“Sernova” or the “Company”) (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) is pleased to announce that it closed $2,000,000 of its non-brokered private placement announced on June 26, 2018. In addition, as the Company has received...
Jul 05, 2018 06:00 am ET
Sernova Initiates Patient Screening and Recruitment for its US Clinical Trial for Diabetes
Sernova Corp. (“Sernova” or the “Company”) (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) announces that patient screening and recruitment has begun in its regenerative medicine US clinical trial for diabetic patients with hypoglycemia unawareness. Sernova’s...
Jun 26, 2018 06:00 am ET
Sernova Announces $2 Million Private Placement Financing
Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH) is pleased to announce that the Company has secured a $1 million institutional lead order in connection with a proposed private placement (the “Offering”) of up to $2 million special warrants...
May 14, 2018 06:00 am ET
Sernova Announces University of Chicago Institutional Review Board (IRB) Approval of the FDA-cleared Therapeutic Cell Pouch Clinical Study
Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), announces today it has received University of Chicago Institutional Review Board (IRB) approval to begin a new clinical protocol for the FDA-cleared human clinical trial to investigate the Cell...
May 08, 2018 06:00 am ET
Sernova Announces U.S. Phase I/II Cell Pouch Clinical Trial with Prominent Diabetes Clinical Investigator
Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), announces Dr. Piotr Witkowski, M.D., Ph.D., a leading expert in type 1 diabetes (T1D) and islet transplantation, as the Clinical Trial Principal Investigator for Sernova’s new clinical study. Dr...
May 04, 2018 06:00 am ET
Sernova Announces Results of 2018 Annual General Meeting of Shareholders and New Chief Financial Officer
Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), announced shareholder approval of all management resolutions brought forward at the 2018 Annual General Meeting held in Vancouver, April 25th. In addition, we are pleased to announce Mr. Sean...
Feb 23, 2018 09:00 am ET
Sernova Obtains FDA Notice of Allowance for Use of Proprietary Cell Pouch System with Continuous Glucose Monitoring Systems in Clinical Trials for Type 1 Diabetes - Video Available on Investmentpitch.
Vancouver, British Columbia--(Newsfile Corp. - February 23, 2018) - Sernova Corp. (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH) a clinical stage company developing regenerative medicine technologies for the treatment of chronic diseases including diabetes and hemophilia, announced that continuous glucose monitoring systems "CGM" (Medtronic Minimed, Northridge, CA) will be provided to patients in Sernova's US regenerative medicine clinical trial of its Cell Pouch™.
Feb 22, 2018 06:00 am ET
Sernova’s Cell Pouch Regenerative Medicine Clinical Trial for Patients with Type 1 Diabetes Supported with Continuous Glucose Monitoring Systems
Continuous Glucose Monitoring System (CGM) to provide sensitive tracking of key efficacy measures in patients at important time points throughout the study
Jan 05, 2018 09:40 am ET
Sernova to Participate at the Biotech Showcase 2018 Healthcare Partnering Conference
LONDON, Ontario, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Sernova Corp (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova’s President and CEO, will be participating at the 10th annual Biotech Showcase...
Dec 11, 2017 08:53 am ET
IIROC Trade Resumption - Sernova Corp.
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2017) - Trading resumes in:
Dec 11, 2017 08:02 am ET
IIROC Trading Resumption - SVA
VANCOUVER, Dec. 11, 2017 /CNW/ - Trading resumes in:
Dec 11, 2017 06:00 am ET
Sernova Receives US FDA IND Allowance to Initiate a US Clinical Trial of its Cell Pouch for the Treatment of Type 1 Diabetes
LONDON, Ontario, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), a clinical stage company developing regenerative medicine technologies for the long-term treatment of diseases including diabetes and hemophilia, is pleased to announce it has received...
Dec 08, 2017 01:57 pm ET
IIROC Trade Halt - Sernova Corp.
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2017) - The following issues have been halted by IIROC:
Dec 08, 2017 01:19 pm ET
IIROC Trading Halt - SVA
VANCOUVER, Dec. 8, 2017 /CNW/ - The following issues have been halted by IIROC:
Aug 15, 2017 06:00 am ET
Sernova Retains FronTier Merchant Capital for North America Investor Relations and Marketing
LONDON, ONTARIO, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), a leading clinical stage regenerative medicine company, is pleased to announce that it has engaged FronTier Merchant Capital Group to provide North American investor relations (IR) and strategic marketing services to the financial community and media across North America with the goal to build shareholder value....
Jun 05, 2017 06:00 am ET
Sernova Provides Company Outlook on Corporate and Clinical Developments
Sernova Corp. (TSX VENTURE: SVA)(FRANKFURT: PSH)(OTCQB: SEOVF), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as hemophilia and other diseases, today provided a brief company outlook on corporate and clinical developments.
Jun 05, 2017 05:58 am ET
Sernova Provides Company Outlook on Corporate and Clinical Developments
Sernova Corp. (TSX VENTURE:SVA)(FRANKFURT:PSH)(OTCQB:SEOVF), a clinical stage company developing medical technologies for the long-term treatment of chronic metabolic diseases including diabetes, blood disorders such as hemophilia and other...
May 05, 2017 06:00 am ET
Sernova Receives Approval to Extend Term of Warrants
Sernova Corp. (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH), a clinical stage regenerative medicine company, is pleased to announce that it has received TSX Venture Exchange acceptance, to extend the expiry date of 5,745,633 share purchase warrants that are exercisable to purchase up to 5,745,633 common shares of Sernova at an exercise price of $0.30 per share, from May 8, 2017 to November 8, 2017. The Company also obtained approval from the TSX Venture Exchange to extend the expiry date of 3,043,256 share purchase warrants that are exercisable to purchase up to 3,043,256 common shares of
May 05, 2017 05:58 am ET
Sernova Receives Approval to Extend Term of Warrants
Sernova Corp. (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH), a clinical stage regenerative medicine company, is pleased to announce that it has received TSX Venture Exchange acceptance, to extend the expiry date of 5,745,633 share purchase warrants...
Dec 22, 2016 06:00 am ET
Sernova to Present Corporate and JDRF-Sponsored Clinical Trial Update at the Biotech Showcase(TM) 2017 Healthcare Conference in San Francisco
Sernova Corp. (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH), a clinical stage regenerative medicine company, is pleased to announce that Dr. Philip Toleikis, Sernova's President and CEO, will present an update on the company's corporate and business strategy at the 9th annual Biotech Showcase Conference in San Francisco, CA. This important conference brings together global industry leaders, emerging companies and key members of the pharmaceutical and investment community.
Dec 22, 2016 05:58 am ET
Sernova to Present Corporate and JDRF-Sponsored Clinical Trial Update at the Biotech Showcase(TM) 2017 Healthcare Conference in San Francisco
Sernova Corp. (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH), a clinical stage regenerative medicine company, is pleased to announce that Dr. Philip Toleikis, Sernova's President and CEO, will present an update on the company's corporate and business...
Nov 02, 2016 11:02 am ET
Sernova and CTI Clinical Trial Announce Regulatory Collaboration
LONDON, Ontario, Nov. 2, 2016 /PRNewswire/ -- Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia and CTI Clinical Trial and Consulting Services (CTI), are pleased to announce their collaboration on regulatory matters respecting Sernova's Cell Pouch System(TM), a novel implantable and scalable medical device that when combined with therapeutic cells, may provide a convenient, safe and effective long-term therapeutic option for p
Nov 02, 2016 06:00 am ET
Sernova and CTI Clinical Trial Announce Regulatory Collaboration
Sernova Corp. (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia and CTI Clinical Trial and Consulting Services (CTI), are pleased to announce their collaboration on regulatory matters respecting Sernova's Cell Pouch System(TM), a novel implantable and scalable medical device that when combined with therapeutic cells, may provide a convenient, safe and effective long-term therapeutic option for patients with chronic diseases such
Nov 02, 2016 05:58 am ET
Sernova and CTI Clinical Trial Announce Regulatory Collaboration
Sernova Corp. (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia and CTI Clinical Trial...
Sep 30, 2016 06:02 am ET
Sernova Announces Appointment of New CFO
Sernova Corp. (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, is pleased to announce today the appointment of Scott Langille as Chief Financial Officer.
Sep 30, 2016 06:02 am ET
Sernova Announces Appointment of New CFO
Sernova Corp. (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, is pleased to announce...
Jul 12, 2016 06:00 am ET
Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patients with Severe Type 1 Diabetes
Sernova Corp. (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, is pleased to announce today it has entered into a research funding agreement with JDRF, the leading global organization funding and advocating for type 1 diabetes (T1D) research. The purpose of the funding is to advance human clinical trials of Sernova's CPS technologies for treatment of hypoglycemia unawareness patients with severe type 1 diabetes. T1D is a
Jul 12, 2016 05:58 am ET
Sernova and JDRF Announce Funding of Joint Research Collaboration to Advance Human Clinical Trials for the Treatment of Hypoglycemic Unawareness Patients with Severe Type 1 Diabetes
Sernova Corp. (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH), a clinical stage company developing disruptive regenerative medicine technologies for the long-term treatment of chronic diseases including diabetes and hemophilia, is pleased to announce...
Jun 30, 2016 06:24 pm ET
Sernova Completes Private Placement of $4,200,000
Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH) is pleased to announce that it has completed a non-brokered private placement of $4.2 million, pursuant to which Sernova issued a total of 16,800,000 units in two closing (June 27, 2016 and June 30, 2016).
Jun 30, 2016 06:24 pm ET
Sernova Completes Private Placement of $4,200,000
Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH) is pleased to announce that it has completed a non-brokered private placement of $4.2 million, pursuant to which Sernova issued a total of 16,800,000 units in...
Jun 29, 2016 09:17 am ET
CORRECTION FROM SOURCE: Sernova Increases Private Placement to $4,200,000
This document corrects and replaces the press release that was sent today at 06:15 ET. Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH) is pleased to announce that it is increasing its...
Jun 29, 2016 09:17 am ET
CORRECTION FROM SOURCE: Sernova Increases Private Placement to $4,200,000
This document corrects and replaces the press release that was sent today at 06:15 ET.
Jun 29, 2016 06:15 am ET
Sernova Increases Private Placement to $4,200,000
Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA)(OTCQB: SEOVF)(FRANKFURT: PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the "Units") at $0.25 per Unit, to accommodate additional over-subscriptions (see our news releases dated June 27, 2016 and June 21, 2016 for further information about the private placement).
Jun 29, 2016 06:15 am ET
Sernova Increases Private Placement to $4,200,000
Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE:SVA)(OTCQB:SEOVF)(FRANKFURT:PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the "Units") at $0.25 per Unit,...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.